AdobeStock_220120304.jpeg

LeapRx

Program Details

Lena Gray, P.T. &

Baby Development Expert

ADVANCE YOUR DISCOVERIES INTO THERAPIES WITH LeapRx

Empire Discovery Institute (EDI) and global pharmaceutical company Novo Nordisk have formed LeapRx, a collaborative research initiative that co-invests in, incubates, and accelerates novel drug discovery programs in cardio-metabolic diseases and rare blood disorders.  Programs of interest include diabetes (type 1 and type 2), obesity, cardiovascular disease, NASH, chronic kidney disease, and rare blood disorders. LeapRx provides:

Access to funding, technical capabilities, and guidance from pharmaceutical industry experts  

Customized project teams dedicated to ensuring scientific and operational success  

Milestone-based workplans co-developed by pharma experts and your institution designed to add patient     and commercial value  

A clearly defined commercial path and exit strategy

FUNDING AND TIMELINE

Total funding of up to $10M over five years for successful programs advancing through the developmental pipeline.  The financial commitment expected to support the first year of each selected program is $250,000.

ELIGIBILITY

LeapRx provides financial support and pharmaceutical industry expertise to aid researchers affiliated with EDI's core academic research labs at the University of Rochester, University at Buffalo, and Roswell Park Comprehensive Cancer Center.  Premier academic research institutions not affiliated with EDI's core labs are also welcome to apply to LeapRx through their technology transfer offices.

FOR MORE INFORMATION, PLEASE CONTACT

Ron Newbold, PhD

E-mail: newboldr@discoverEDI.org

MEET OUR PARTNERING TEAM

Director of Portfolio Development and Alliance Management

Ron_photo.jpg
sebastian_novo photo.jpg
Uli Stilz.png

Ron Newbold
EDI

Sebastian Beck Jorgensen
Novo Nordisk

Uli Stilz
Novo Nordisk

logo final_.png